Conflict of interest: None.
Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis
Article first published online: 12 SEP 2013
© 2013 Wiley Periodicals, Inc.
Journal of Cellular Biochemistry
Volume 114, Issue 11, pages 2471–2478, November 2013
How to Cite
Shiozawa, Y., McGee, S., Pienta, M. J., McGregor, N., Jung, Y., Yumoto, K., Wang, J., Berry, J. E., Pienta, K. J. and Taichman, R. S. (2013), Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J. Cell. Biochem., 114: 2471–2478. doi: 10.1002/jcb.24592
- Issue published online: 12 SEP 2013
- Article first published online: 12 SEP 2013
- Accepted manuscript online: 20 MAY 2013 09:39AM EST
- Manuscript Accepted: 3 MAY 2013
- Manuscript Received: 10 JAN 2013
- National Institutes of Health. Grant Numbers: P50 CA69568, P30 CA46592
- National Cancer Institute. Grant Numbers: CA093900, CA163124
- Department of Defense
- Prostate Cancer Foundation
Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta-analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk. J. Cell. Biochem. 114: 2471–2478, 2013. © 2013 Wiley Periodicals, Inc.